GlassScriptPhysician profile
Timothy Ray Olive
NPI 1033418439
$1,922.49
in general payments reported to CMS, 2019-2025
29 companies · $264 in 2025
The $264 reported for 2025 was more than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $354 · 2022: $295 · 2023: $450 · 2024: $560 · 2025: $264.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,249 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,249.06 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $317.56 | 2021-2025 | Farxiga, Airsupra, Lokelma |
| Glaxosmithkline, LLC. | $244.01 | 2021-2025 | Trelegy Ellipta, Arexvy |
| Novo Nordisk INC | $181.29 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $135.98 | 2021-2024 | Jardiance |
| Janssen Pharmaceuticals, INC | $108.48 | 2022-2024 | Xarelto |
| Pfizer INC. | $106.10 | 2021-2024 | |
| Abbvie INC. | $93.68 | 2021-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $93.53 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $92.97 | 2021-2023 | |
| Exact Sciences Corporation | $80.81 | 2023-2024 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $61.13 | 2024-2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $51.94 | 2022-2023 | |
| Lilly USA, LLC | $44.71 | 2021-2025 | Zepbound, Mounjaro |
| Currax Pharmaceuticals LLC | $41.53 | 2023 | Nexletol, Onzetra Xsail, Nexlizet |
| Xeris Pharmaceuticals, INC. | $30.51 | 2022-2023 | Gvoke Hypopen |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $28.30 | 2025 | Gemtesa |
| Lundbeck LLC | $25.98 | 2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $22.34 | 2025 | Fanapt |
| Dexcom, INC. | $20.23 | 2025 | Dexcom G6 Transmitter |
| Amgen INC. | $17.33 | 2023 | Prolia |
| Viatris Specialty LLC | $17.09 | 2025 | Yupelri |
| Metacel Pharmaceuticals LLC | $15.41 | 2022 | |
| Eisai INC. | $15.15 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $14.58 | 2021 | |
| Merck Sharp & Dohme LLC | $13.78 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.06 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $13.01 | 2022 | |
| Sunovion Pharmaceuticals INC. | $11.36 | 2021 | |
| Athena Bioscience, LLC | $10.64 | 2024 | Nexiclon Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Olive listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.